Q-omics provides the consensus-scored MIR5692B profile across patient tissues and cancer cell-line models. MIR5692B expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR5692B is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, MIR5692B RNA expression shows 11,453 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, THCA, and THYM as cancer lineages where MIR5692B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5692B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5692B survival associations across molecular data types. MIR5692B RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5692B RNA expression–survival associations across cancer types. High MIR5692B expression shows unfavorable associations in CESC, CHOL, READ, LIHC, SARC and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for MIR5692B RNA expression.
This table summarizes MIR5692B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5692B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5692B shows lower tumor expression in THCA, ESCA, KIRP and KIRC and higher tumor expression in PRAD and LUAD. The THCA box plot shows higher MIR5692B RNA expression in normal versus tumor tissue (log2 FC = −1.371, t-test p < 0.001).
This table shows molecular features associated with MIR5692B in patient tissues and cancer cell lines. In patient samples, MIR5692B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
